Robert will be accountable for the Company’s Regulatory Affairs function including strategic leadership and operational execution of all regulatory activities related to the development and registration of Oxular’s product pipeline.
Robert brings over 15 years of extensive expertise in the development and registration of drug products and devices in ophthalmology. He joins Oxular from Astellas in Leiden where he has been working as a Global Regulatory Lead on urology and ophthalmology projects.
Previously he worked at Allergan for nearly 10 years in various key European regulatory roles including Head of Ophthalmology and Head of Regulatory Development. At Allergan Robert led a number of teams responsible for obtaining drug product approvals in glaucoma and back of eye diseases including the European registration of OZURDEX™ for RVO, Uveitis and DME.
Robert also spent 5 years at Bausch & Lomb where he gained early experience developing ophthalmic drug device combinations for the US & Europe.
Robert is a registered Pharmacist and holds a PhD in Analytical Chemistry from The School of Pharmacy, University of London.
As a young company, we are proud to attract somebody of Robert’s calibre within the ophthalmology field
Tom Cavanagh, Chief Executive Officer of Oxular Ltd, commented: “We are delighted to welcome Robert to the Oxular team. Robert’s deep knowledge in global regulation combined with his extensive experience in progressing ophthalmology projects to approval will be a great asset to the Company as we look to bring new ophthalmic products to market. As a young company, we are proud to attract somebody of Robert’s calibre within the ophthalmology field and we believe that he will play a key role in helping us to achieve our goal of building a global ophthalmic franchise based on the successful development and commercialisation of our innovative and much needed treatments for retinal diseases.”
